Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies
Current Cancer Drug Targets
3-dioxygenase (IDO); Cancer immunotherapy; Combination therapy; IDO inhibitors; Immune tolerance; Indoleamine 2
© 2016 Bentham Science Publishers. Indoleamine 2, 3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.
Selvan, S., Dowling, J., Kelly, W., & Lin, J. (2016). Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies. Current Cancer Drug Targets, 16 (9). http://dx.doi.org/10.2174/1568009615666151030102250